Volume 1, 2018
MEETING REPORT

Outcomes and Lessons From the First CDRI-NRDC- Industry Conclave

pdf
  • Sabyasachi Sanyal
    ,
  • Saman Habib
    ,
  • Ritu Trivedi
    ,
  • K. V. Sashidhara
    ,
  • Kishor Mohanan
    ,
  • Amit Misra
Sabyasachi Sanyal
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
Saman Habib
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
Ritu Trivedi
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
K. V. Sashidhara
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
Kishor Mohanan
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
Amit Misra
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, Uttar Pradesh 226 031
DOI: https://doi.org/10.29195/DSSS.01.01.0002

Published 2023-09-04

Keywords

  • Pharmaceutical Industry; Drug Discovery; Industry-Academia Interaction; Research Priorities; Funding; Science Policy.

How to Cite

Sanyal, S., Habib, S., Trivedi, R., Sashidhara, K. V., Mohanan, K., & Misra, A. (2023). Outcomes and Lessons From the First CDRI-NRDC- Industry Conclave. DIALOGUE: Science, Scientists and Society, 1, 1–16. https://doi.org/10.29195/DSSS.01.01.0002
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

The first Industry Conclave organized jointly by the CSIR-CDRI and the National Research Development Corporation (NRDC) was held on 15–16 September 2017. This document summarizes the learnings from the formal panel discussions conducted during the meeting, as well as interactions among the delegates during the exhibition that showcased the CDRI product pipeline, services offered and proposals for collaborative R&D. It became evident during the course of the conclave that although there was broad consensus on the societal and intellectual value of pursuing ‘basic’ science, there is a significant ‘trust deficit’ between the Indian academia and the Industry. Research funding and its sources, and evaluation of research output continue to be contentious.

pdf

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

  1. Barton, A. C., J. L. Ermer, et al. (2003). Teaching Science for Social Justice. New York, Teachers College Press, Columbia University.
  2. Bennett, S., J. D. Quick, et al. (1997). Public-Private Roles in the Pharmaceutical Sector: Implications for equitable access and rational drug use. Geneva, World Health Organization.
  3. Endo, A. (1992). "The discovery and development of HMG-CoA reductase inhibitors." J. Lipid Res. 33(11): 1569-1582.
  4. Jekunen, A. (2014). Decision-Making in Product Portfolios of Pharmaceutical Research and Development – Managing Streams of Innovation in Highly Regulated Markets. Drug Design, Development and Therapy 8: 2009–2016.
  5. Lauterbur, P. C. (1989). Image formation by induced local interactions. Examples employing nuclear magnetic resonance. 1973. Clin. Orthop. Relat. Res.(244): 3-6.
  6. Markel, H. (2013). Patents, profits, and the American people--the Bayh-Dole Act of 1980. N. Engl. J. Med. 369(9): 794-796.
  7. Marsh, N. and A. Marsh (2000). A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin. Exp. Pharmacol. Physiol. 27(4): 313-319.
  8. Morgan, S., P. Grootendorst, et al. (2011). The cost of drug development: a systematic review. Health Policy 100(1): 4-17.
  9. Sarewitz, D. and R. Nelson (2008). Three rules for technological fixes. Nature 456(7224): 871- 872.
  10. Stevens, A. J., J. J. Jensen, et al. (2011). The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364(6): 535-541.
  11. Tobert, J. A. (2003). Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. 2(7): 517-526.
  12. Wahi, V., N. K. Ganguly, et al. (1989). "Enzyme immunoassay (ELISA) for the detection of anticarbohydrate antibodies in rheumatic fever and rheumatic heart disease." Jpn. J. Exp. Med.